Crinetics Pharmaceuticals to be Acquired by Vertex for $10 Billion in Cash
CRNX has more than doubled off its 52-week low of $25.83 on elevated volume (4.1× avg).
Summary
Crinetics Pharmaceuticals announced it will be acquired by Vertex Pharmaceuticals for $85.00 per share in cash, valuing the company at approximately $10.0 billion.
Key Events · M&A and Partnerships · CRNX
-
Definitive Acquisition Agreement
Crinetics Pharmaceuticals has entered into a definitive agreement to be acquired by Vertex Pharmaceuticals for $85.00 per share in cash.
-
Significant Transaction Value
The total equity value of the acquisition is approximately $10.0 billion, or $8.8 billion net of estimated cash acquired.
-
Substantial Shareholder Premium
The offer price represents a 101% premium to Crinetics' closing stock price on July 2, 2026, and a 127% premium to its 30-day VWAP as of the same date.
-
Expected Closing Timeline
The transaction is anticipated to close in the third quarter of 2026, subject to Crinetics shareholder approval and regulatory clearances.
Analysis · CRNX · Life Sciences
This filing confirms the definitive agreement for Vertex Pharmaceuticals to acquire Crinetics Pharmaceuticals for $85.00 per share in cash, a deal valued at approximately $10.0 billion. This represents a complete buyout of the company at a substantial premium for shareholders, fundamentally altering the company's future and investment thesis. The transaction is expected to close in Q3 2026, pending shareholder and regulatory approvals.
At the time of this filing, CRNX was trading at $84.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $25.83 to $57.99. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.